Renata receives UK approval for esomeprazole tablets
Renata PLC has received marketing authorisation (MA) in the United Kingdom for Esomeprazole 20 mg and 40 mg gastro-resistant tablets, approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The product, marketed in Bangladesh under the brand name Maxpro MUPS, is indicated for the management of gastro-oesophageal reflux disease (GERD), treatment of erosive reflux oesophagitis, prolonged treatment following intravenous-induced prevention of rebleeding of peptic ulcers, and treatment of Zollinger–Ellison syndrome.
The product is manufactured using Multiple Unit Pellet System (MUPS) technology, which incorporates multiple enteric-coated pellets within each tablet. This formulation allows uniform dispersion in the gastrointestinal tract, resulting in more consistent intestinal absorption and reducing the risk of dose dumping. The gastro-resistant formulation also prevents premature degradation of the drug, ensuring targeted release at the intended site of absorption, thereby improving efficacy and tolerability.
Keep updated, follow The Business Standard's Google news channel
Renata introduced MUPS technology to the Bangladeshi market, significantly influencing the local esomeprazole segment by setting benchmarks in formulation efficiency and therapeutic reliability. Maxpro MUPS has since become one of the most recognised brands in the gastrointestinal category. Together, Maxpro and Maxpro MUPS are among Renata's highest-selling products in Bangladesh and are widely prescribed by healthcare professionals.
The UK approval marks a significant milestone for Renata, as one of its flagship formulations enters a highly regulated international market. The development reflects the company's progression from local pharmaceutical innovation to global regulatory acceptance and highlights its growing capability to deliver value-added medicines to international markets.
